Unexpected side effects linked to efgartigimod alfa use in MG
A recent study identified adverse events attributed to efgartigimod alfa use that are not currently listed in the drug’s manual.
News
-
-
Key inflammatory biomarker associated with fatigue in MG
C-reactive protein was significantly associated with fatigue in MG.
-
Study finds patients with myasthenia gravis carried heavy anxiety burden in pandemic
Patients with myasthenia gravis faced significant health-related anxiety during COVID-19, especially due to infection and treatment risks.
-
Advanced-onset myasthenia gravis shows unique risks and symptoms
Patients with AOMG have more bulbar problems, lower prevalence of thymoma, less aggressive treatment approaches and higher mortality rates.
-
Study finds racial and social disparities in rates of MG symptom flare-ups
Black patients had a higher risk of flare-ups than white patients, even after taking income and health insurance coverage into consideration.
-
New research drives personalized care for myasthenia gravis
Doctors are learning that different types of myasthenia gravis respond better to treatments designed for each specific subtype.
-
Study explores factors of early response to efgartigimod for myasthenia gravis
Efgartigimod therapy showed notable efficacy in treating generalized myasthenia gravis.
-
Lower iron levels may increase risk of myasthenia gravis
Individuals who are genetically predisposed to have lower iron levels may be at an elevated risk of developing MG, a recent study found.
-
Researchers uncover distinct immune drivers in late-onset myasthenia gravis
Late-onset myasthenia gravis showed different immune activity than early-onset cases, suggesting unique disease mechanisms.
-
Patients with MG adopt different strategies to cope with diagnosis
Positive attitude, problem solving and support seeking are some strategies used by patients with MG to manage their condition.
